Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
Lamotrigine vs APTIOM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Stabilizes neuronal membranes by blocking voltage-gated sodium channels and inhibiting the release of excitatory neurotransmitters, particularly glutamate and aspartate.
Selective enhancement of slow inactivation of voltage-gated sodium channels, stabilizing neuronal membranes and inhibiting excitatory neurotransmitter release.
Bipolar I disorder (maintenance treatment),Partial-onset seizures (adjunctive therapy),Primary generalized tonic-clonic seizures (adjunctive therapy),Lennox-Gastaut syndrome (seizures),Off-label: neuropathic pain, trigeminal neuralgia, schizophrenia augmentation
Adjunctive therapy in the treatment of partial-onset seizures in patients with epilepsy
Initial: 25 mg orally once daily for 2 weeks, then 50 mg once daily for 2 weeks, then increase by 50 mg every 1-2 weeks. Maintenance: 100-200 mg twice daily (200-400 mg/day). Maximum: 400 mg/day.
Initial: 50 mg orally once daily; titrate at weekly intervals by 50 mg twice daily increments to maintenance dose of 200 mg twice daily (400 mg/day). Maximum: 400 mg twice daily (800 mg/day).
25.4 h (range 24-31 h, prolonged to 59 h with valproate)
Terminal elimination half-life ranges from 20 to 48 hours (mean ~32 hours). Steady-state achieved within 5-7 days.
Primarily metabolized by UDP-glucuronosyltransferases (UGT1A4, UGT2B7). Minimal involvement of CYP450 enzymes. Autoinduction of its own metabolism with chronic use.
Primarily glucuronidation via UGT2B7; also metabolized by CYP3A4, CYP2C19, and CYP1A2 to a lesser extent.
Renal (94% as metabolites, 10% unchanged; 2% fecal)
Primarily eliminated by hepatic metabolism, with approximately 95% excreted as metabolites in urine and <2% as unchanged drug. Fecal excretion accounts for about 5%.
55% (binds to albumin)
Approximately 90% bound to human plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
1.2 L/kg (distribution into tissues, including brain)
Volume of distribution is approximately 1.3 L/kg, suggesting extensive distribution into tissues.
Oral: 98% (immediate-release); ~90% (extended-release)
Oral bioavailability is approximately 60% (range 53-68%).
e GFR <30 m L/min/1.73 m²: use with caution; no specific dose adjustment recommended. e GFR <10 m L/min: reduce dose by 50% and monitor.
Estimated creatinine clearance (Cr Cl) >50 m L/min: no adjustment. Cr Cl 30-50 m L/min: reduce maintenance dose by 50%; Cr Cl <30 m L/min and not on hemodialysis: not recommended. Hemodialysis: 50 mg once daily with supplement of 25 mg after dialysis.
Child-Pugh Class B: reduce dose by 50%. Child-Pugh Class C: reduce dose by 75%.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce maintenance dose by 50%; initiate at 50 mg once daily, titrate slowly. Child-Pugh Class C: contraindicated.
2-12 years: 0.15 mg/kg/day once daily for 2 weeks, then 0.3 mg/kg/day once daily for 2 weeks, then increase by 0.3 mg/kg/day every 1-2 weeks. Maintenance: 1-5 mg/kg/day divided twice daily. Maximum: 400 mg/day.
Children (≥4 years): Initial 1.5 mg/kg/day orally divided twice daily; titrate weekly by increments of 1.5 mg/kg/day to a maintenance of 3-6 mg/kg/day twice daily. Maximum: 400 mg twice daily.
Lower initial doses (25 mg every other day) and slower titration due to increased sensitivity and slower clearance; monitor for adverse effects.
No specific dose adjustment based on age alone. Dose selection should be cautious, reflecting higher frequency of decreased renal/hepatic function and concomitant disease or drug therapy. Consider creatinine clearance and titrate slowly.
Life-threatening rashes, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), especially in pediatric patients and with rapid dose escalation.
None
Risk of serious rash (SJS/TEN); hemophagocytic lymphohistiocytosis (HLH); aseptic meningitis; multiorgan hypersensitivity reactions; suicidal thoughts and behavior; blood dyscrasias; cardiac conduction abnormalities; increased seizure frequency with abrupt withdrawal.
Suicidal behavior and ideation,Angioedema,Anaphylaxis,Dermatological reactions including Stevens-Johnson syndrome,Decreased serum sodium,Dizziness and gait disturbance,Hepatic injury
Hypersensitivity to lamotrigine or any component of the formulation.
Known hypersensitivity to eslicarbazepine acetate or any oxcarbazepine derivative
No significant food interactions. Grapefruit has no effect. Alcohol may increase CNS depression and dizziness; limit or avoid.
Take with or without food. No specific food interactions reported.
First trimester exposure increases risk of oral clefts (cleft lip/palate) (absolute risk ~0.3-0.9% vs 0.2% background). Second/third trimester: risk of neural tube defects, cardiac malformations, and developmental delay. Higher doses (>300 mg/day) and polytherapy increase risk. Folate supplementation recommended.
Pregnancy Category D. First trimester: Increased risk of major congenital malformations, including neural tube defects, craniofacial defects, and cardiac anomalies. Second and third trimesters: Risk of fetal antiepileptic drug syndrome (facial dysmorphism, growth retardation, neurodevelopmental delay). Neonatal hemorrhage due to vitamin K deficiency may occur.
Lamotrigine is excreted into breast milk with a milk-to-plasma ratio of approximately 0.6. Infant serum concentrations can reach 25-50% of maternal levels. Risk of rash, apnea, drowsiness; benefits likely outweigh risks in most cases. Monitor infant for adverse effects.
Excreted in human milk. Milk-to-plasma ratio not established. Potential for serious adverse reactions in nursing infants (sedation, poor suckling). Use only if benefit outweighs risk; consider alternative anticonvulsants.
Clearance increases by 50-330% during pregnancy, particularly in second and third trimesters. Dose may need to be increased (up to 2-3 times pre-pregnancy dose) to maintain therapeutic levels. Postpartum clearance returns to baseline within 1-2 weeks, requiring dose reduction to avoid toxicity.
Pregnancy increases clearance of eslicarbazepine acetate by approximately 30-40% in the second and third trimesters. Dose may require up to 50-100% increase from baseline to maintain therapeutic levels. Postpartum clearance returns rapidly; reduce dose promptly to avoid toxicity.
Titrate slowly to minimize risk of Stevens-Johnson syndrome; start 25 mg/day for weeks 1–2, then 50 mg/day for weeks 3–4. Drug interactions: valproate doubles lamotrigine half-life and increases SJS risk; estrogen-containing contraceptives reduce lamotrigine levels by ~50%. Therapeutic serum level: 2.5–15 mcg/m L. Monitor for rash, especially in first 8 weeks.
APTIOM (eslicarbazepine acetate) is a once-daily antiepileptic drug for partial-onset seizures. Monitor serum sodium, especially in elderly or those on concomitant hyponatremia-inducing drugs. Titrate to maintenance dose over 2 weeks. Avoid abrupt discontinuation. Contraindicated in second- or third-degree AV block.
Report any rash, hives, or blisters immediately; may be sign of serious skin reaction.,Do not stop taking abruptly; taper under doctor's guidance to avoid rebound seizures.,Take missed dose as soon as remembered unless close to next dose; do not double.,Oral contraceptives and hormone therapy can reduce lamotrigine effectiveness; discuss with doctor.,Avoid driving or operating machinery until effects are known; may cause dizziness or blurred vision.
Take exactly as prescribed once daily; do not crush or chew tablets.,Report symptoms of hyponatremia: nausea, headache, confusion, lethargy.,Do not stop abruptly; withdrawal may increase seizure frequency.,Avoid driving until effects on dizziness or somnolence are known.,Notify doctor if pregnant, planning pregnancy, or breastfeeding.,Use effective contraception as APTIOM may reduce hormonal contraceptive efficacy.
"Telithromycin is a potent inhibitor of CYP3A4, while lamotrigine is primarily metabolized by UGT1A4 and not significantly by CYP3A4. However, telithromycin may also inhibit UGT1A4, leading to reduced lamotrigine clearance and increased risk of lamotrigine toxicity, including severe rash (Stevens-Johnson syndrome) and central nervous system depression. Concurrent use may require lamotrigine dose adjustment to avoid adverse effects."
"Concomitant use of Lormetazepam, a benzodiazepine that enhances GABAergic inhibition, and Lamotrigine, a sodium channel blocker and glutamate release inhibitor, may result in additive central nervous system depression and an increased risk of sedation, dizziness, and psychomotor impairment. The interaction is primarily pharmacodynamic, as both drugs have CNS depressant effects, potentially leading to excessive drowsiness and impaired coordination. Clinical outcomes may include increased fall risk, cognitive dysfunction, and compromised ability to perform tasks requiring alertness."
"Concurrent use of paliperidone and lamotrigine may increase the risk of central nervous system depression and synergistic adverse effects, including sedation, dizziness, and impaired cognitive function. Paliperidone, an atypical antipsychotic, and lamotrigine, an anticonvulsant, both modulate neurotransmitter systems, potentially leading to additive pharmacodynamic effects. Clinically, this can result in increased sedation, confusion, and an elevated risk of falls or accidents, particularly in elderly patients."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about Lamotrigine vs APTIOM, answered by our medical review team.
Lamotrigine is a Anticonvulsant that works by Stabilizes neuronal membranes by blocking voltage-gated sodium channels and inhibiting the release of excitatory neurotransmitters, particularly glutamate and aspartate.. APTIOM is a Anticonvulsant that works by Selective enhancement of slow inactivation of voltage-gated sodium channels, stabilizing neuronal membranes and inhibiting excitatory neurotransmitter release.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between Lamotrigine and APTIOM depend on the specific clinical indication. These are both Anticonvulsant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of Lamotrigine is: Initial: 25 mg orally once daily for 2 weeks, then 50 mg once daily for 2 weeks, then increase by 50 mg every 1-2 weeks. Maintenance: 100-200 mg twice daily (200-400 mg/day). Maximum: 400 mg/day.. The standard adult dose of APTIOM is: Initial: 50 mg orally once daily; titrate at weekly intervals by 50 mg twice daily increments to maintenance dose of 200 mg twice daily (400 mg/day). Maximum: 400 mg twice daily (800 mg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between Lamotrigine and APTIOM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. Lamotrigine is classified as Category A/B. First trimester exposure increases risk of oral clefts (cleft lip/palate) (absolute risk ~0.3-0.9% vs 0.2% background). Second/third trimester: risk of neural tube defects, cardiac. APTIOM is classified as Category C. Pregnancy Category D. First trimester: Increased risk of major congenital malformations, including neural tube defects, craniofacial defects, and cardiac anomalies. Second and thir. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.